Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms: early-phase trial registry
50 of 160 indexed Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #68 of 28,707 conditions by registered trial count.
160 US clinical trials · 50 currently recruiting · #68 of 28,707 conditions by registered trial count
Neoplasms: 160 US clinical trials tracked, 50 recruiting.
Neoplasms is the subject of 160 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 15 of these trials.
Enrollment posture brief
Registry condition neoplasms
OPEN 50 | RECR 31% | LATE 9 | EARLY 99 | RANK #68 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)
Neoplasms lists 50 open slots (31% of 160 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms is recruiting below its size-band peers.
50 of 160 indexed trials (31.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neoplasms trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 15 of 160 trials (9.4%). 85 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasms enrolment sits around 81 participants.
Median target enrolment is 81 among the 159 trials that report a genuine target (sentinel values excluded). 87 of those (54.7%) plan for fewer than 100 participants.
-
Neoplasms research is mostly interventional.
130 interventional and 30 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
160 total, page 2 of 4
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
Wendie Berg
NCT04085510
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
NCT04607421
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
Tesaro
NCT03981796
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Tesaro
NCT02715284
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro
NCT02817633
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development
NCT02908906
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai
NCT04008797
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Alliance for Clinical Trials in Oncology
NCT04711109
Extended Access of Momelotinib in Adults With Myelofibrosis
GlaxoSmithKline
NCT03441113
M7824 Related Adverse Effects in Adults With Cancer
National Cancer Institute (NCI)
NCT04267861
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
NCT03194893
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
Janssen Research & Development
NCT04606381
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT05277051
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
NCT04958239
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience
NCT05103358
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT04446351
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Uswm CT
NCT03967223
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT03843359
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Uswm CT
NCT06703346
Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients
Cedars-Sinai Medical Center
NCT03757182
Hispanic Adapted and Culturally Relevant Exercising Together
University of Arizona
NCT06018311
Time-Restricted Eating to Address Persistent Cancer-Related Fatigue
University of Maryland, Baltimore
NCT05256888
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
NCT03602157
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
GlaxoSmithKline
NCT06077877
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
NCT02690545
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Cancer Institute (NCI)
NCT05797246
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT02663297
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
NCT05993299
Concordance Between ctDNA Assay and FoundationOne
Foundation Medicine
NCT02620527
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Celgene
NCT01964430
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
Sanofi
NCT00417079
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT02410512
REST: Reducing End-of-Life Symptoms With Touch
National Center for Complementary and Integrative Health (NCCIH)
NCT00065195
Enhanced Self-Efficacy Training
Duke University
NCT00938769
Views of Cancer Patients Regarding Financial Conflicts of Interest
National Institutes of Health Clinical Center (CC)
NCT00097682
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT03449381
Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings
UNC Lineberger Comprehensive Cancer Center
NCT04931251
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Immatics US
NCT03760952
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
Tesaro
NCT03329001
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma
NCT02632448
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
Norwegian University of Science and Technology
NCT02330926
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
Stanford University
NCT00725387
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT02219724
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
NCT01373164
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Duke University
NCT00939146
Exercise Intervention for LGBT Cancer Survivors
University of Rochester
NCT02459769
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Pfizer
NCT02222922
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
NCT03099174
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Pfizer
NCT00443534
Livestrong Cancer Institutes' Patient Reported Outcomes Study
University of Texas at Austin
NCT04627077
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 18 |
| Phase 3 | 7 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms page
160 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms condition card totals 160 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.